0001387131-20-006168.txt : 20200702
0001387131-20-006168.hdr.sgml : 20200702
20200702163424
ACCESSION NUMBER: 0001387131-20-006168
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200630
FILED AS OF DATE: 20200702
DATE AS OF CHANGE: 20200702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TPG Group Holdings (SBS) Advisors, Inc.
CENTRAL INDEX KEY: 0001495741
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39344
FILM NUMBER: 201009937
BUSINESS ADDRESS:
STREET 1: C/O TPG GLOBAL, LLC
STREET 2: 301 COMMERCE STREET, SUITE 3300
CITY: FORT WORTH
STATE: TX
ZIP: 76102
BUSINESS PHONE: 817-871-4000
MAIL ADDRESS:
STREET 1: C/O TPG GLOBAL, LLC
STREET 2: 301 COMMERCE STREET, SUITE 3300
CITY: FORT WORTH
STATE: TX
ZIP: 76102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BONDERMAN DAVID
CENTRAL INDEX KEY: 0000860866
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39344
FILM NUMBER: 201009938
MAIL ADDRESS:
STREET 1: 301 COMMERCE STREET
STREET 2: SUITE 3300
CITY: FORT WORTH
STATE: TX
ZIP: 76102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COULTER JAMES G
CENTRAL INDEX KEY: 0001099776
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39344
FILM NUMBER: 201009939
MAIL ADDRESS:
STREET 1: 301 COMMERCE STREET
STREET 2: SUITE 3300
CITY: FORT WORTH
STATE: TX
ZIP: 76102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fusion Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001805890
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
BUSINESS PHONE: 289-799-0891
MAIL ADDRESS:
STREET 1: 270 LONGWOOD ROAD SOUTH
CITY: HAMILTON
STATE: A6
ZIP: L8P 0A6
4
1
ownership.xml
X0306
4
2020-06-30
1
0001805890
Fusion Pharmaceuticals Inc.
FUSN
0001495741
TPG Group Holdings (SBS) Advisors, Inc.
C/O TPG GLOBAL, LLC
301 COMMERCE STREET, SUITE 3300
FORT WORTH
TX
76102
0
0
0
1
Former 10% Owner
0000860866
BONDERMAN DAVID
C/O TPG GLOBAL, LLC
301 COMMERCE STREET, SUITE 3300
FORT WORTH
TX
76102
0
0
0
1
Former 10% Owner
0001099776
COULTER JAMES G
C/O TPG GLOBAL, LLC
301 COMMERCE STREET, SUITE 3300
FORT WORTH
TX
76102
0
0
0
1
Former 10% Owner
Common Stock
2020-06-30
4
C
0
2301794
0.00
A
2301794
I
See Explanation of Responses (1)(2)(4)5)
Common Stock
2020-06-30
4
P
0
250000
17.00
A
2551794
I
See Explanation of Responses
Class A Preferred Shares
2020-06-30
4
C
0
8000000
D
Common Shares
1498406
0
I
See Explanation of Responses
Class B Preferred Shares
2020-06-30
4
C
0
4289296
D
Common Stock
803388
0
I
See Explanation of Responses
David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotech GenPar V Advisors, LLC, which is the general partner of TPG Biotechnology GenPar V, L.P., which is the general partner of TPG Biotechnology Partners V, L.P. ("TPG Biotech V"), which directly holds (i) 2,551,794 Common Shares ("Common Shares") of Fusion Pharmaceuticals Inc. (the "Issuer") and (ii) 371,819 Class B Preferred Share Purchase Warrants of the Issuer.
Pursuant to the Articles of the Issuer (as amended, the "Articles"), on June 30, 2020, the (a) Class A Preferred Shares of the Issuer held by TPG Biotech V automatically converted into 1,498,406 Common Shares and (b) Class B Preferred Shares (together with the Series A Preferred Shares, the "Preferred Shares") of the Issuer held by TPG Biotech V automatically converted into 803,388 Common Shares. Pursuant to the Articles, the Preferred Shares had been convertible, at the option of the holder, at any time into Common Shares at an initial conversion rate equal to one Common Share per Preferred Share. The initial conversion rate had been adjusted as a result of a 1-for-5.339 reverse share split of the Common Shares.
On June 30, 2020, in connection with the Issuer's initial public offering, TPG Biotech V acquired 250,000 shares of Common Stock at a price of $17.00 per share.
Because of the relationship between the Reporting Persons and TPG Biotech V, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech V. Each of TPG Biotech V and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech V's or such Reporting Person's pecuniary interest therein, if any.
Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.
(6) The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. (7) Gerald Neugebauer is signing on behalf of both Messrs. Bonderman and Coulter pursuant to authorization and designation letters dated February 26, 2020, which were previously filed with the Securities and Exchange Commission.
/s/ Michael LaGatta, Vice President, TPG Group Holdings (SBS) Advisors, Inc. (6)
2020-07-02
/s/ Gerald Neugebauer on behalf of David Bonderman (6)(7)
2020-07-02
/s/ Gerald Neugebauer on behalf of James G. Coulter (6)(7)
2020-07-02